PA Medical News about sunitinib

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Use of Antiemetic Agents in Acute Gastroenteritis

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases
Cancer, 07/01/09

Kao J et al. - Addition of SU (25 to 37.5 mg) to IGRT is tolerable in patients with oligometastases, without potentiation of RT toxicity. On the basis of promising antitumor responses observed with this novel combination, a multi-institutional phase 2 trial using SU 37.5 mg/RT 50 Gy is ongoing.

<< Previous
Cancer treatment adherence among low-income women with breast or...

Next >>
Oral Contraceptives: A Risk Factor for Squamous Cell Carcinoma

Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
British Journal of Cancer, 10/19/09 Relevance Score: 89%

Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate
Investigational New Drugs, 10/08/09 Relevance Score: 88%

Electrocardiographic Characterization of the QTc Interval in Patients with Advanced Solid Tumors: Pharmacokinetic- Pharmacodynamic Evaluation of Sunitinib
Clinical Cancer Research, 11/16/09 Relevance Score: 87%

Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature
Medical Oncology, 10/23/09 Relevance Score: 87%

Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-2a compared with sunitinib
British Journal of Cancer, 11/20/09 Relevance Score: 84%